Tesamorelin 20mg
Tesamorelin 20 mg — Comprehensive Summary
Basic Information
| Item | Details |
|---|---|
| Name | Tesamorelin |
| Type | GHRH analog (stimulates growth hormone release) |
| Strength | 20 mg lyophilized powder |
| Approved Use | HIV-associated lipodystrophy (FDA-approved) |
| Route | Subcutaneous injection (SC) |
Reconstitution
| Item | Method |
|---|---|
| Solvent | 3 mL bacteriostatic water |
| Final Concentration | 6.67 mg/mL |
| Storage | Lyophilized powder: refrigerate (2–8 °C) Reconstituted solution: refrigerate, use under sterile conditions |
Common Dosage Reference
| Week | Dose | Micrograms (mcg) | U100 Syringe Units | Injection Volume (mL) |
|---|---|---|---|---|
| Week 1 | 1 mg/day | 1000 mcg | ~15 units | 0.15 mL |
| Week 2+ | 2 mg/day | 2000 mcg | ~30 units | 0.30 mL |
-
Frequency: Once daily, ideally in the evening to match natural GH rhythm.
-
Cycle length: Typically 8–16 weeks, depending on goals and tolerance.
Precautions & Monitoring
1. Tolerance Check: Start at 1 mg/day for the first week, then increase to 2 mg/day.
2. Possible Side Effects: Injection site reactions, joint pain, edema, blood sugar fluctuations.
3. Monitoring: IGF‑1 levels, blood glucose, lipids, and overall response.
4. Safety: Use only under medical supervision; maintain sterile technique and proper storage.
Practical Tips
1. U100 syringe conversion: 1 mL = 100 units
2. Dose-volume reference:
1 mg ≈ 0.15 mL ≈ 15 units
2 mg ≈ 0.30 mL ≈ 30 units
Write your message here and send it to us
